Harvard Bioscience is a developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and preclinical testing for drug development. Co.'s Cellular and Molecular Technologies (CMT) product family includes products designed primarily to support the discovery phase of new drug development. CMT products include syringe and peristaltic pump product lines, as well as a range of instruments and accessories for tissue, organ-based lab research. Co.'s Preclinical product family provides a platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The HBIO stock yearly return is shown above.
The yearly return on the HBIO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the HBIO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|